A regimen utilizing 5-fluorouracil at a dose of 30–35 mg/kg as one single rapid injection was contrasted with a schedule of 5- fluorouracil administered rapidly, intravenously at a dose of 13.5 mg/kg/day for each of five successive days in a randomized clinical trial in 98 patients with various metastatic adenocarcinomas. Fifty-one of these patients had carcinoma whose primary site of origin was unknown. Nine of 50 patients had an objective regression on the 5-day schedule (8 of 25 with unknown primaries) contrasted with 1 of 48 (0 of 26 with unknown primaries) regressions utilizing a single injection technique. The toxicity encountered included myelosuppression in about 60% of patients in both groups but gastrointestinal side effects were statistically significantly less utilizing the single injection technique. In this group of patients, 5-fluorouracil as a single injection technique proved to be significantly inferior compared to the conventional 5-day course of this drug.

Keywords:
Chemotherapy, 5-Fluorouracil, Carcinoma
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.